We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Quintiles' (Q) OCE Software to Simplify Commercial Functions
Read MoreHide Full Article
In an initiative to streamline pharmaceutical commercial functions, QuintilesIMS announced the general availability of Orchestrated Customer Engagement (OCE), a SaaS software. The software is expected to be available by this winter.
OCE eases out the commercial functions of multi-channel marketing, customer relationship management, medical affairs and market access.
We expect OCE SaaS software to strengthen the company’s commercial solutions business, which grew just 2.4% in the last reported quarter. Growth in the segment was impacted by the lackluster performance of the legacy Quintile Encore business, which declined over 50% year over year. The latest pharmaceutical-commercial development is likely to bolster the company’s footprint in the niche markets.
Notably, OCE leverages on Quintiles’ flagship Ada (an artificial-intelligence feature), Apollo and Lexi features. Lexi is an application program interface (API) layer that connects all applications across an enterprise. Per management, OCE’s unique procedure of task integration, decision making and sales and marketing convergence makes it highly unique in the niche space.
Meanwhile, we are upbeat on the company’s solid full-year guidance. The company expects total revenue in the band of $8 billion to $8.1 billion and adjusted EBITDA in the range of $2 billion to $2.1 billion.
Stock Performance
Despite the positive development, shares of Quintiles inched 1% down to close at $90.18, following the news release. In fact, Quintiles’s performance lacked luster over the last one month. The company gained just 4.9%, lower than the Zacks categorized Medical Services sub-industry’s addition of almost 7.9%.
However, the current level compares favorably with the S&P 500’s return of just 1.1% over the same time frame. This, together with a long-term expected earnings growth rate of 12.9%, instills confidence in investors.
Furthermore, the estimate revision for the stock has been favorable. The year has seen seven estimates move north over the last two months, compared with no movement in the opposite direction. As a result, full-year estimates rose 1.1% to $4.53 over the same time frame.
Quintiles carries a Zacks Rank #3 (Hold).
Key Picks
Better-ranked stocks in the broader medical sector include Inogen Inc. (INGN - Free Report) , CryoLife, Inc. and Luminex Corporation . Notably, Inogen and Luminex sport a Zacks Rank #1 (Strong Buy), while CryoLife carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Inogen has a long-term expected earnings growth rate of 17.50%. Notably, the stock represents an impressive one-year return of 99.5%.
Luminex has a long-term expected earnings growth rate of 16.25%. Additionally, the stock represents an impressive one-year return of 20.3%.
CryoLife represents a strong return of 70.3% over the last one year. The stock posted a positive earnings surprise of 80% in the last reported quarter.
Sell These Stocks. Now.
Just released, today's 220 Zacks Rank #5 Strong Sells demand urgent attention. If any are lurking in your portfolio or Watch List, they should be removed immediately. These sinister companies because many appear to be sound investments. However, from 1988 through 2016, stocks from our Strong Sell list have actually performed 6X worse than the S&P 500.
Image: Bigstock
Quintiles' (Q) OCE Software to Simplify Commercial Functions
In an initiative to streamline pharmaceutical commercial functions, QuintilesIMS announced the general availability of Orchestrated Customer Engagement (OCE), a SaaS software. The software is expected to be available by this winter.
OCE eases out the commercial functions of multi-channel marketing, customer relationship management, medical affairs and market access.
We expect OCE SaaS software to strengthen the company’s commercial solutions business, which grew just 2.4% in the last reported quarter. Growth in the segment was impacted by the lackluster performance of the legacy Quintile Encore business, which declined over 50% year over year. The latest pharmaceutical-commercial development is likely to bolster the company’s footprint in the niche markets.
Notably, OCE leverages on Quintiles’ flagship Ada (an artificial-intelligence feature), Apollo and Lexi features. Lexi is an application program interface (API) layer that connects all applications across an enterprise. Per management, OCE’s unique procedure of task integration, decision making and sales and marketing convergence makes it highly unique in the niche space.
Meanwhile, we are upbeat on the company’s solid full-year guidance. The company expects total revenue in the band of $8 billion to $8.1 billion and adjusted EBITDA in the range of $2 billion to $2.1 billion.
Stock Performance
Despite the positive development, shares of Quintiles inched 1% down to close at $90.18, following the news release. In fact, Quintiles’s performance lacked luster over the last one month. The company gained just 4.9%, lower than the Zacks categorized Medical Services sub-industry’s addition of almost 7.9%.
However, the current level compares favorably with the S&P 500’s return of just 1.1% over the same time frame. This, together with a long-term expected earnings growth rate of 12.9%, instills confidence in investors.
Furthermore, the estimate revision for the stock has been favorable. The year has seen seven estimates move north over the last two months, compared with no movement in the opposite direction. As a result, full-year estimates rose 1.1% to $4.53 over the same time frame.
Quintiles carries a Zacks Rank #3 (Hold).
Key Picks
Better-ranked stocks in the broader medical sector include Inogen Inc. (INGN - Free Report) , CryoLife, Inc. and Luminex Corporation . Notably, Inogen and Luminex sport a Zacks Rank #1 (Strong Buy), while CryoLife carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Inogen has a long-term expected earnings growth rate of 17.50%. Notably, the stock represents an impressive one-year return of 99.5%.
Luminex has a long-term expected earnings growth rate of 16.25%. Additionally, the stock represents an impressive one-year return of 20.3%.
CryoLife represents a strong return of 70.3% over the last one year. The stock posted a positive earnings surprise of 80% in the last reported quarter.
Sell These Stocks. Now.
Just released, today's 220 Zacks Rank #5 Strong Sells demand urgent attention. If any are lurking in your portfolio or Watch List, they should be removed immediately. These sinister companies because many appear to be sound investments. However, from 1988 through 2016, stocks from our Strong Sell list have actually performed 6X worse than the S&P 500.
See today's Zacks ""Strong Sells"" absolutely free >>